These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28785316)

  • 1. Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring.
    Torimoto K; Okada Y; Koikawa K; Tanaka Y
    Diabetol Metab Syndr; 2017; 9():60. PubMed ID: 28785316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
    Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM).
    Matsumura M; Nakatani Y; Tanka S; Aoki C; Sagara M; Yanagi K; Suzuki K; Aso Y
    Diabetes Ther; 2017 Aug; 8(4):821-827. PubMed ID: 28646412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Li K; Xu G
    J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
    Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
    Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
    Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
    Hayashi A; Takano K; Kawai S; Shichiri M
    Endocr J; 2016; 63(2):187-91. PubMed ID: 26549210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
    Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Sakai K; Murohara T; Ajioka M
    Geriatr Gerontol Int; 2018 Jan; 18(1):108-114. PubMed ID: 28861952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring.
    Uemura F; Okada Y; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2018 Feb; 20(2):140-146. PubMed ID: 29293363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms and efficacy of SGLT2 inhibitors].
    Shiba T
    Nihon Rinsho; 2015 Mar; 73(3):438-46. PubMed ID: 25812370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use.
    Goto Y; Otsuka Y; Ashida K; Nagayama A; Hasuzawa N; Iwata S; Hara K; Tsuruta M; Wada N; Motomura S; Tajiri Y; Nomura M
    Endocr Connect; 2020 Jul; 9(7):599-606. PubMed ID: 32580152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.